Risk-adapted Therapy for Primary Acute Myeloid Leukemia

12 mg/m2/day; intravenous, administration at induction phase, days 1 to 3.

"200mg/m2/day, intravenous at induction phase; days 1-7.~\- High dose during consolidation phase. In patients up to 60 years 3g/m2/12hours days 1,3,5, and patients 60 to 70 years: 1.5g/m2/12hours days 1,3,5."

"* Administration at induction phase to remission days 1 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatment arises 30x10e9/L.~* Administration at consolidation phase day 7."

To be performed in patients in the intermediate or adverse risk groups.

To be considered in patients in the intermediate risk group without an available allogeneic donor and negative measurable residual disease, per center decision.

To be performed either with molecular monitoring or, if not applicable, by flow cytometry. Pre-stablished cut-off values are defined for decision-making.